2015 AAN Medical Meeting Reporter: Advances in B-Cell and Other Novel Therapeutics in Multiple Sclerosis

Pre-Activity Questions

Please use the below scale to rate your current level of confidence in your ability to: *

1=Not at all confident, 5=Extremely confident, N/A=Not applicable for me

	1	2	3	4	5	N/A
Develop personalized treatment plans for patients with multiple sclerosis	Develop personalized treatment plans for patients with multiple sclerosis - 1	Develop personalized treatment plans for patients with multiple sclerosis - 2	Develop personalized treatment plans for patients with multiple sclerosis - 3	Develop personalized treatment plans for patients with multiple sclerosis - 4	Develop personalized treatment plans for patients with multiple sclerosis - 5	Develop personalized treatment plans for patients with multiple sclerosis - N/A
Integrate B-cell targeted therapies into your therapy selection in multiple sclerosis patients	Integrate B-cell targeted therapies into your therapy selection in multiple sclerosis patients - 1	Integrate B-cell targeted therapies into your therapy selection in multiple sclerosis patients - 2	Integrate B-cell targeted therapies into your therapy selection in multiple sclerosis patients - 3	Integrate B-cell targeted therapies into your therapy selection in multiple sclerosis patients - 4	Integrate B-cell targeted therapies into your therapy selection in multiple sclerosis patients - 5	Integrate B-cell targeted therapies into your therapy selection in multiple sclerosis patients - N/A

B cell targeted therapies are being investigated as a possible therapy for patients who are unsuccessful on other therapies. Results from a phase II study of rituximab given as two infusions separated by 14 days and evaluated every six months showed to be well tolerated. Which of the following clinical results were observed? *

a. 90% reduction in GAD-enhancing lesions; 50% reduction in clinical attacks

b. 50% reduction in GAD-enhancing lesions; 50% reduction in clinical attacks

c. 50% reduction in GAD-enhancing lesions; 90% reduction in clinical attacks

d. No reduction in GAD-enhancing lesions; 50% reduction in clinical attacks

Phenytoin is hypothesized to have a neuroprotective effect in patients with optic neuritis. When given early to patients with optic neuritis, a 30% reduction in which of the following was seen in patients given phenytoin compared to those not given phenytoin? *

a. Clinical outcomes

b. Retinal fiber thickness

c. Retinal fiber thickness and macular volume

A 45-year old multiple sclerosis patient inquires about her diet and how it may help manage her disease symptoms. She wants to know if she should consume a high fat, high fiber, or low salt diet. Which of these has not been proven to have either a negative or positive effect on MS patients? *

a. High fat

b. High fiber

c. Low salt

d. High fat and high fiber

Data involving vitamin D levels in multiple sclerosis patients has accumulated over the past few years in relation to disease risk and disease course. Some data presented at AAN 2015 suggested vitamin D is an immunomodulator. Which proinflammatory cytokine may vitamin D effect the production of? *

a. IL-5

b. IL-6

c. IL-15

d. IL-17

Using the scale below, please indicate how often you currently use these practice strategies. *

Use scale: 1=Never, 2=Not often, 3=Sometimes, 4=Often, 5=Always, N/A= Not applicable to me

	1	2	3	4	5	N/A
Consider the pathophysiology of multiple sclerosis and the role of B-cells when developing treatment plans for patients	Consider the pathophysiology of multiple sclerosis and the role of B-cells when developing treatment plans for patients - 1	Consider the pathophysiology of multiple sclerosis and the role of B-cells when developing treatment plans for patients - 2	Consider the pathophysiology of multiple sclerosis and the role of B-cells when developing treatment plans for patients - 3	Consider the pathophysiology of multiple sclerosis and the role of B-cells when developing treatment plans for patients - 4	Consider the pathophysiology of multiple sclerosis and the role of B-cells when developing treatment plans for patients - 5	Consider the pathophysiology of multiple sclerosis and the role of B-cells when developing treatment plans for patients - N/A
Implement clinical trial data for novel therapeutics in multiple sclerosis	Implement clinical trial data for novel therapeutics in multiple sclerosis - 1	Implement clinical trial data for novel therapeutics in multiple sclerosis - 2	Implement clinical trial data for novel therapeutics in multiple sclerosis - 3	Implement clinical trial data for novel therapeutics in multiple sclerosis - 4	Implement clinical trial data for novel therapeutics in multiple sclerosis - 5	Implement clinical trial data for novel therapeutics in multiple sclerosis - N/A
Utilize B-cell targeted therapies in the management of patients with multiple sclerosis.	Utilize B-cell targeted therapies in the management of patients with multiple sclerosis. - 1	Utilize B-cell targeted therapies in the management of patients with multiple sclerosis. - 2	Utilize B-cell targeted therapies in the management of patients with multiple sclerosis. - 3	Utilize B-cell targeted therapies in the management of patients with multiple sclerosis. - 4	Utilize B-cell targeted therapies in the management of patients with multiple sclerosis. - 5	Utilize B-cell targeted therapies in the management of patients with multiple sclerosis. - N/A

Leave this field blank

Elsevier CME

2015 AAN Medical Meeting Reporter: Advances in B-Cell and Other Novel Therapeutics in Multiple Sclerosis

Pre-Activity Questions

Pre-Activity Questions

Course Video

Post-Activity Test

Evaluation

Course navigation

You are here

2015 AAN Medical Meeting Reporter: Advances in B-Cell and Other Novel Therapeutics in Multiple Sclerosis

Pre-Activity Questions

Pre-Activity Questions

Course Video

Post-Activity Test

Evaluation

Course navigation